![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi Halts Trial Evaluating Hemophilia Drug
Sanofi Halts Trial Evaluating Hemophilia Drug
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
November 10, 2020
Sanofi has halted a global phase 3 trial evaluating its investigational hemophilia drug fitusiran after reports of adverse events.
Fitusiran is a once-monthly, subcutaneously administered drug designed to treat hemophilia A and B by blocking antithrombin, a protein that inhibits blood clotting and causes excessive bleeding.
Sanofi halted the study following a recommendation by the trial’s independent data monitoring committee. The company said it is investigating reports of nonfatal thrombotic events in trial participants.
Upcoming Events
-
21Oct